Welcome to our dedicated page for Calidi Biotherapeutics news (Ticker: CLDI), a resource for investors and traders seeking the latest updates and insights on Calidi Biotherapeutics stock.
Calidi Biotherapeutics Inc. (NYSE American: CLDI) is a clinical-stage biotechnology leader developing novel stem cell-based delivery systems for oncolytic virotherapies. This page provides investors and researchers with timely updates on clinical developments, strategic partnerships, and scientific breakthroughs in cancer treatment innovation.
Access comprehensive coverage of CLDI's progress across its therapeutic platforms, including CLD-101 for high-grade gliomas and RTNova for metastatic cancers. Our curated news collection features verified updates on trial milestones, regulatory filings, and peer-reviewed research findings essential for understanding the company's trajectory.
Key updates include developments in Phase 1b/2 clinical trials, technology licensing agreements, and advancements in systemic virotherapy delivery systems. All content undergoes rigorous verification to ensure accuracy in reporting complex biopharmaceutical developments.
Bookmark this page for streamlined access to Calidi's latest press releases, investor communications, and analysis of its stem cell platform's potential across oncology and regenerative medicine applications. Stay informed about critical developments in next-generation cancer therapies through our maintained news repository.
Calidi Biotherapeutics (NYSE:CLDI) will be featured on Bloomberg TV's RedChip Small Stocks, Big Money™ show on March 1, 2025, at 7 p.m. ET. During the interview, CFO Andrew Jackson discusses the company's oncolytic virotherapy (OV) platforms for cancer treatment.
The company's technology utilizes stem cells to protect, amplify, and enhance oncolytic viruses for targeting cancer cells. Their pipeline includes CLD-101, currently in Phase 1/1b trials with upcoming Phase 1b/2 study, and CLD-201 targeting Phase 1 initiation in 2025. The company estimates its addressable U.S. market at $13-15 billion.
Calidi Biotherapeutics (NYSE American: CLDI) has announced the start of recruitment for a new CLD-101 clinical trial at Northwestern University Hospital. The trial will focus on patients with newly diagnosed high-grade glioma, an aggressive form of brain cancer. The company has completed shipping the first batch of CLD-101, which combines allogeneic neural stem cells with oncolytic adenovirus CRAd-S-pk7.
This Phase 1B/2 trial, led by Dr. Maciej Lesniak and Dr. Roger Stupp, will implement a multiple-dose regime, building upon a previous Phase 1 trial that showed promising results with single doses in 12 patients. The study has received NIH/NCI SPORE funding and aims to enhance therapeutic efficacy in newly diagnosed patients. The trial is particularly significant as it involves Dr. Stupp, known for developing the FDA-approved Stupp Protocol for Glioblastoma treatment.
Calidi Biotherapeutics (NYSE American: CLDI) has announced an upcoming live investor webinar scheduled for February 5, 2025, at 4:15 p.m. ET. The event will feature presentations from CFO Andrew Jackson and CSO Antonio F. Santidrian, who will discuss the company's cell-based delivery platforms for enhanced cancer treatment.
The webinar will showcase Calidi's leading programs, including CLD-400 for metastatic cancers, CLD-201 for advanced solid tumors, and CLD-101 for high-grade glioma. The event, hosted by RedChip Companies, will include a live Q&A session with management. Investors can register for free and submit questions in advance or during the event.
Calidi Biotherapeutics (NYSE: CLDI) reported a cash balance of $9.6 million as of December 31, 2024, and announced the termination of its Standby Equity Purchase Agreement (SEPA) with YA II PN, effective January 23, 2025. The company secured significant funding through multiple channels in Q4 2024, including $9.5 million from public offerings, $2.0 million from warrant exercises, and $3.1 million from its ATM facility. In January 2025, an additional public offering raised $4.25 million in gross proceeds.
The company's strengthened financial position led to the termination of the unused SEPA, which had provided the option to sell up to $25 million of common stock over three years. Recent developments include the acceptance of their RTNova platform abstract for presentation at the AACR Annual Meeting and FDA clearance for a Phase 1b/2 trial of CLD-101 for high-grade gliomas, scheduled to begin enrollment in Q1 2025.
Calidi Biotherapeutics (NYSE: CLDI) announced the acceptance of its abstract for presentation at the AACR Annual Meeting in Chicago (April 25-30, 2025). The presentation, titled 'Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites,' will showcase data from their proprietary RTNova systemic platform.
The platform features a novel vaccinia virus strain enveloped with human cell membrane (extracellular enveloped virus or EEV), designed to target distant tumors while avoiding immune system elimination. This technology aims to address treatment challenges in advanced-stage metastatic cancers, particularly when intratumoral administration isn't feasible.
The company also plans to submit additional data about RTNova's lead clinical candidate selection at the ASCO Annual Meeting in June 2025. This development complements Calidi's existing clinical and preclinical work on localized and intratumoral cell-based virotherapies with SNV (SuperNova) and NNV (NeuroNova).
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted antitumor virotherapies, has completed its previously announced public offering. The company sold 5,000,000 shares of common stock at $0.85 per share, raising gross proceeds of approximately $4.25 million.
Ladenburg Thalmann & Co. Inc. served as the exclusive placement agent for the offering, which was conducted under an effective Form S-3 registration statement. The final prospectus was filed with the SEC on January 10, 2025, and is available through the SEC's website and Ladenburg Thalmann & Co. Inc.
Calidi Biotherapeutics (NYSE AMERICAN: CLDI) has announced the pricing of its public offering of 5,000,000 shares of common stock at $0.85 per share, expecting to raise gross proceeds of approximately $4.25 million. The offering is expected to close on January 10, 2025, with Ladenburg Thalmann & Co. Inc. acting as exclusive placement agent.
The company plans to use the net proceeds for working capital and general corporate purposes. The offering is being made through a shelf registration statement on Form S-3, which was declared effective by the SEC on October 10, 2024.
Calidi is a clinical-stage biotechnology company developing targeted immunotherapies, with proprietary technology focused on arming the immune system to fight cancer through stem cell-based platforms carrying oncolytic viruses for multiple oncology indications.
Calidi Biotherapeutics (NYSE AMERICAN: CLDI), a clinical-stage biotechnology company focused on targeted immunotherapies, has announced plans for a public offering of common stock and pre-funded warrants. The offering will be conducted through Ladenburg Thalmann & Co. Inc. as the exclusive placement agent.
The company intends to use the proceeds for working capital and general corporate purposes. The securities will be offered through a shelf registration statement on Form S-3 that was declared effective by the SEC on October 10, 2024. The final size, terms, and completion of the offering are subject to market conditions.
A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC, providing detailed information about the offering terms.
Calidi Biotherapeutics presented data at IOVC and SITC conferences showcasing their RTNova™ systemic enveloped virotherapy technology for targeting metastatic lung cancer. The technology utilizes a tumor-selective vaccinia virus engineered to produce extracellular enveloped viruses (EEVs), designed to target multiple metastatic tumor sites while avoiding immune system clearance.
The data demonstrated RTNova's therapeutic potential in an advanced lung metastasis model, both as a monotherapy and as a viral vector for delivering therapeutic payloads. The technology shows promise in killing and transforming tumor microenvironments across multiple sites, potentially offering new treatment options for previously untreatable metastatic diseases.
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted antitumor virotherapies, has completed its previously announced public offering of 4,437,869 shares of common stock. The shares were priced at $1.69 per share, generating gross proceeds of approximately $7.5 million. Ladenburg Thalmann & Co. Inc. served as the exclusive placement agent for the offering, which was conducted under an effective Form S-3 registration statement.
